PTC Therapeutics secures Russian approval for Translarna to treat Duchenne muscular dystrophy
PTC Therapeutics, a leading US-based biotechnology company, has received marketing approval in Russia for its innovative drug, Translarna (ataluren), designed to treat patients with Duchenne ... Read More
PTC Therapeutics completes $200m acquisition of Agilis Biotherapeutics to expand gene therapy portfolio
In a major strategic move, US biopharmaceutical company PTC Therapeutics has finalized its acquisition of Agilis Biotherapeutics, a biotech firm specializing in the development of ... Read More